Title: Principal Investigator E-mail:


9/1998 – 6/2002 B.Sc. (Biomedicine), College of Life Sciences, Wuhan University, China

9/2002 – 6/2007 Ph.D. (Microbiology), College of Life Sciences, Wuhan University, China

Research Interests

The major goals are to select full-length antibodies and antibody fragments against important and emerging viruses by phage display, yeast display, and other high throughput screening technologies; develop novel single domain antibodies based on scaffolds derived from antibody constant CH2 domains in antibody Fc fragments; and improve biological activities of Fc fragments. We try to elucidate the basic questions (e.g., understand the mechanism of virus-host interactions) in virology, and solve several difficulties for improvement of yield of protein-related drugs during the research and development of therapeutic antibodies (e.g., improve the efficiency of correct folding in proteins).


*corresponding author

1.           Sun Y, Zhang H, Shi J, Zhang Z, Gong R*. Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Viruses. 2017, 9(9).

2.           Chen X, Zeng F, Huang T, Cheng L, Liu H*, Gong R*. Optimization on Fc for Improvement of Stability and Aggregation Resistance. Curr Pharm Biotechnol. 2016, 17(15):1353-1359.

3.           Shi J, Zhang H, Gong R*, Xiao G*. Characterization of the fusion core in zebrafish endogenous retroviral envelope protein. Biochem Biophys Res Commun. 2015, 460(3):633-8.

4.           Guo L, Zhang Z, Gong R*, Xiao G*. Real-time quantitative PCR assay for rapid detection of murine virus contamination in bioproducts. Virol Sin. 2014, 29(3):193-5.

5.           Gong R*, Xiao G. Engineered antibody variable and constant domains as therapeutic candidates. Pharm Pat Anal. 2013, 2(5):637-46.

6.           Gong R*, Wang Y, Ying T, Feng Y, Streaker E, Prabakaran P, Dimitrov DS*. N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance. Mol Pharm. 2013, 10(7):2642-52.

7.           Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R*, Dimitrov DS*. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. Virol Sin. 2013, 28(2):71-80.

8.           Gong R*, Wang Y, Ying T, Dimitrov DS. Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn. PLoS One. 2012, 7(8):e42288.

9.           Gehlsen K$*, Gong R$, Bramhill D, Wiersma D, Kirkpatrick S, Wang Y, Feng Y, Dimitrov DS. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs. 2012, 4(4):466-74. ($contributed equally)

10.       Gong R*, Chen W, Dimitrov DS. Candidate antibody-based therapeutics against HIV-1. BioDrugs. 2012, 26(3):143-62.

11.       Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS*. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal fc receptor. J Biol Chem. 2011, 286(31):27288-93.

12.       Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS*. Engineered human antibody constant domains with increased stability. J Biol Chem. 2009, 284(21):14203-10.

13.       Gong R, Huang L, Shi J, Luo K, Qiu G, Feng H, Tien P, Xiao G*. Syncytin-A mediates the formation of syncytiotrophoblast involved in mouse placental development. Cell Physiol Biochem. 2007, 20(5):517-26.

14.       Gong R, Peng X, Kang S, Feng H, Huang J, Zhang W, Lin D, Tien P*, Xiao G*. Structural characterization of the fusion core in syncytin, envelope protein of human endogenous retrovirus family W. Biochem Biophys Res Commun. 2005, 331(4):1193-200.

15.       Li D, Gong R, Zheng J, Chen X*, Dimitrov DS, Zhao Q*. Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation. Biochem Biophys Res Commun. 2017, 485(2):446-453.

16.       Ying T*, Wang Y, Feng Y, Prabakaran P, Gong R, Wang L, Crowder K, Dimitrov DS. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs. 2015, 7(5):922-30.

17.       Ying T*, Gong R, Ju TW, Prabakaran P, Dimitrov DS. Engineered Fc based antibody domains and fragments as novel scaffolds. Biochim Biophys Acta. 2014, 1844(11):1977-82.

18.       Zu X, Liu Y, Wang S, Jin R, Zhou Z, Liu H, Gong R, Xiao G*, Wang W*. Peptide inhibitor of Japanese encephalitis virus infection targeting envelope protein domain III. Antiviral Res. 2014, 104C:7-14.

19.       Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, Dimitrov DS*. Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains. Curr Drug Discov Technol. 2014, 11(1):28-40.

20.       Ying T*, Chen W, Feng Y, Wang Y, Gong R, Dimitrov DS. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem. 2013, 288(35):25154-64.

21.       Prabakaran P*, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, Dimitrov DS. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol. 2012, 3:277.

22.       Ying T*, Chen W, Gong R, Feng Y, Dimitrov DS. Soluble Monomeric IgG1 Fc. J Biol Chem. 2012, 287(23):19399-408.

23.       Chen W, Feng Y, Gong R, Zhu Z, Wang Y, Zhao Q, Dimitrov DS*. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol. 2011, 85(18):9395-405.

24.       Feng Y*, Gong R, Dimitrov DS. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor. Protein Expr Purif. 2011, 79(1):66-71.

25.       Peng X, Pan J, Gong R, Liu Y, Kang S, Feng H, Qiu G, Guo D, Tien P, Xiao G*. Functional characterization of syncytin-A, a newly murine endogenous virus envelope protein: implication for its fusion mechanism. J Biol Chem. 2007, 282(1):381-9

26.       Sha Y, Wu Y, Cao Z, Xu X, Wu W, Jiang D, Mao X, Liu H, Zhu Y, Gong R, Li W. A convenient cell fusion assay for the study of SARS-CoV entry and inhibition. IUBMB Life. 2006, 58(8):480-6.

27.       Sun G, Guo M, Shen A, Mei F, Peng X, Gong R, Guo D, Wu J, Tien P*, Xiao G*. Bovine PrPC directly interacts with alphaB-crystalline. FEBS Lett. 2005, 579(24):5419-24.